AU2004238546A1 - Pharmaceutical composition comprising valsartan - Google Patents

Pharmaceutical composition comprising valsartan Download PDF

Info

Publication number
AU2004238546A1
AU2004238546A1 AU2004238546A AU2004238546A AU2004238546A1 AU 2004238546 A1 AU2004238546 A1 AU 2004238546A1 AU 2004238546 A AU2004238546 A AU 2004238546A AU 2004238546 A AU2004238546 A AU 2004238546A AU 2004238546 A1 AU2004238546 A1 AU 2004238546A1
Authority
AU
Australia
Prior art keywords
visit
patient
trial
valsartan
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004238546A
Other languages
English (en)
Inventor
Jay Norman Cohn
Robert Dean Glazer
Robert Latini
Aldo Pietro Maggioni
Gianni Tognoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004238546A1 publication Critical patent/AU2004238546A1/en
Priority to AU2008246267A priority Critical patent/AU2008246267B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004238546A 2003-05-16 2004-05-14 Pharmaceutical composition comprising valsartan Abandoned AU2004238546A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008246267A AU2008246267B2 (en) 2003-05-16 2008-11-20 Pharmaceutical composition comprising valsartan

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47113703P 2003-05-16 2003-05-16
US60/471,137 2003-05-16
PCT/EP2004/005204 WO2004101535A1 (en) 2003-05-16 2004-05-14 Pharmaceutical composition comprising valsartan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008246267A Division AU2008246267B2 (en) 2003-05-16 2008-11-20 Pharmaceutical composition comprising valsartan

Publications (1)

Publication Number Publication Date
AU2004238546A1 true AU2004238546A1 (en) 2004-11-25

Family

ID=33452429

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004238546A Abandoned AU2004238546A1 (en) 2003-05-16 2004-05-14 Pharmaceutical composition comprising valsartan
AU2008246267A Ceased AU2008246267B2 (en) 2003-05-16 2008-11-20 Pharmaceutical composition comprising valsartan

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008246267A Ceased AU2008246267B2 (en) 2003-05-16 2008-11-20 Pharmaceutical composition comprising valsartan

Country Status (10)

Country Link
US (2) US20070054947A1 (https=)
EP (1) EP1631556A1 (https=)
JP (1) JP4783733B2 (https=)
CN (1) CN1816533A (https=)
AU (2) AU2004238546A1 (https=)
BR (1) BRPI0410374A (https=)
CA (1) CA2525665A1 (https=)
MX (1) MXPA05012299A (https=)
TW (1) TW200509909A (https=)
WO (1) WO2004101535A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080066776A (ko) * 2005-11-08 2008-07-16 노파르티스 아게 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP3178812A1 (en) * 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
WO2013147137A1 (ja) * 2012-03-30 2013-10-03 味の素株式会社 心不全の治療剤
AU2013304949C1 (en) 2012-08-24 2020-12-24 Novartis Ag NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling
ES2968541T3 (es) * 2013-08-26 2024-05-10 Novartis Ag Tratamiento de enfermedades cardiovasculares
CN106414416B (zh) * 2014-09-09 2020-03-27 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
WO2019241519A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
WO2019241590A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
CN115317478B (zh) * 2022-08-26 2023-05-02 宁波大学 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
US6596747B2 (en) * 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
CA2360305A1 (en) * 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
EP1332131A2 (en) * 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2002053161A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
US6395782B1 (en) * 2001-03-02 2002-05-28 Wisconsin Alumni Research Foundation Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid
EP1406611A2 (en) * 2001-05-30 2004-04-14 Alteon, Inc. Method for treating fibrotic diseases or other indications
JP2005509631A (ja) * 2001-10-18 2005-04-14 ノバルティス アクチエンゲゼルシャフト Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
WO2004101535A1 (en) 2004-11-25
CN1816533A (zh) 2006-08-09
AU2008246267A1 (en) 2008-12-11
AU2008246267B2 (en) 2011-02-17
US20070054947A1 (en) 2007-03-08
US20090105322A1 (en) 2009-04-23
TW200509909A (en) 2005-03-16
BRPI0410374A (pt) 2006-06-13
CA2525665A1 (en) 2004-11-25
EP1631556A1 (en) 2006-03-08
MXPA05012299A (es) 2006-01-30
JP2006528949A (ja) 2006-12-28
JP4783733B2 (ja) 2011-09-28

Similar Documents

Publication Publication Date Title
AU2008246267B2 (en) Pharmaceutical composition comprising valsartan
EP0741567B1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
US9592231B2 (en) Therapy for complications of diabetes
JP6810152B2 (ja) サクビトリルおよびバルサルタンの組合せの新規使用
JP4173098B2 (ja) キマーゼ阻害剤及びａｃｅ阻害剤を有効成分として含有する薬剤
EP1513519B1 (en) The use of substituted cyanopyrrolidines for treating hyperlipidemia
RS66371B1 (sr) Nova upotreba kombinacije blokera angiotenzinskih receptora (arb) sa neutralnim inhibitorom endopeptidaze (nepi)
TW200831078A (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
WO1996031234A1 (en) Combination compositions containing benazepril or benazeprilat and valsartan
JP4525964B2 (ja) 肺高血圧症予防治療剤
JP2021020917A (ja) サクビトリルおよびバルサルタンの組合せの新規使用
CA3252232A1 (en) METHODS OF TREATMENT OF SEGMENTAL AND FOCAL GLOMERULOSCLEROSIS WITH ATRASENTAN
HK1180956A (en) Therapy for complications of diabetes
ZA200403199B (en) Method for the treatment of overactive bladder.
EP2033646A1 (en) Prophylactic and/or therapeutic agent for rheumatoid arthritis
JPWO2004019926A1 (ja) 心不全の予防及び／又は治療剤
MX2007014396A (es) Composicion farmaceutica que comprende 1-(3-clorofenil)-3- alquilpiperazina para el tratamiento de trastorno alimenticio.
HK1074794B (en) The use of substituted cyanopyrrolidines for treating hyperlipidemia
WO1998041199A1 (fr) Decongestionnant nasal ou oculaire

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted